Quest for the right Drug
פמטרקסד אוור פארמה 25 מ"ג/מ"ל PEMETREXED EVER PHARMA 25 MG/ML (PEMETREXED AS DISODIUM)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
תרכיז להכנת תמיסה לאינפוזיה : CONCENTRATE FOR SOLUTION FOR INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Summary of the safety profile The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis. Other undesirable effects include renal toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash, infection/sepsis and neuropathy. Rarely seen events include Stevens-Johnson syndrome and toxic epidermal necrolysis. Tabulated list of adverse reactions The table 4 lists the adverse drug events regardless of causality associated with pemetrexed used either as a monotherapy treatment or in combination with cisplatin from the pivotal registration studies (JMCH, JMEI, JMBD, JMEN and PARAMOUNT) and from the post marketing period. ADRs are listed by MedDRA body system organ class. The following convention has been used for classification of frequency: very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1000; very rare: <1/10,000 and not known (cannot be estimated from available data). Table 4. Frequencies of all grades adverse drug events regardless of causality from the pivotal registration studies: JMEI (pemetrexed vs docetaxel), JMDB (pemetrexed and cisplatin versus gemcitabine and cisplatin), JMCH (pemetrexed plus cisplatin versus cisplatin), JMEN and PARAMOUNT (pemetrexed plus best supportive care versus placebo plus best supportive care) and from post-marketing period. System Organ Very common Common Uncommon Rare Very rare Not known Class (MedDRA) Infections and Infectiona Sepsisb Dermo- infestations Pharyngitis hypodermitis Blood and Neutropenia Febrile Pancytopenia Autoimmune lymphatic Leukopenia neutropenia haemolytic system Haemoglobin Platelet count anaemia disorders decreased decreased Immune Hyper- Anaphylactic System sensitivity shock disorders Metabolism Dehydration and nutrition disorders Nervous Taste disorder Cerebro- system Peripheral vascular disorders motor accident neuropathy Ischaemic Peripheral stroke sensory Haemorrhage neuropathy intracranial Dizziness Eye disorders Conjunctivitis Dry eye Lacrimation increased Kerato- conjunctivitis sicca Eyelid oedema Ocular surface disease System Organ Very common Common Uncommon Rare Very rare Not known Class (MedDRA) Cardiac Cardiac failure Angina disorders Arrhythmia Myocardial infarction Coronary artery disease Arrhythmia supra- ventricular Vascular Peripheral disorders ischaemiac Respiratory, Pulmonary thoracic and embolism mediastinal Interstitial disorders pneumonitisbd Gastrointestinal Stomatitis Dyspepsia Rectal disorders Anorexia Constipation haemorrhage Vomiting Abdominal Gastro- Diarrhea pain intestinal Nausea haemorrhage Intestinal perforation Oesophagitis Colitise Hepatobiliary Alanine amino- Hepatitis disorders transferase increased Aspartate amino- transferase increased System Organ Very common Common Uncommon Rare Very rare Not known Class (MedDRA) Skin and Rash Hyper- Erythema Stevens- subcutaneous Skin pigmentation Johnson tissue disorders exfoliation Pruritus syndromeb Erythema Toxic multiforme epidermal Alopecia necrolysisb Urticaria Pemphigoid Dermatitis bullous Acquired epidermolysis bullosa Erythematous oedemaf Pseudocell ulitis Dermatitis Eczema Prurigo Renal and Creatinine Renal failure Nephrogenic urinary clearance Glomerular diabetes disorders decreased filtration rate insipidus Blood decreased Renal tubular creatinine necrosis increasede General Fatigue Pyrexia disorders and Pain administration Oedema site conditions Chest pain Mucosal inflammation Investigations Gamma- glutamyl- transferase increased Injury, Radiation Recall poisoning and oesophagitis phenomenon procedural Radiation complications pneumonitis a with and without neutropenia b in some cases fatal c sometimes leading to extremity necrosis d with respiratory insufficiency Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף
עלון מידע לרופא
03.12.23 - עלון לרופאעלון מידע לצרכן
לתרופה במאגר משרד הבריאות
פמטרקסד אוור פארמה 25 מ"ג/מ"ל